Navamedic ASA acquires marketing authorisations for antibiotics in the Nordics
(Oslo, May 12, 2020)
Navamedic has entered into a term sheet with ACS Dobfar and InfoRLife to acquire the marketing authorisations for a series of antibiotics for hospital use in the Nordic region. This is an important step in Navamedic’s growth strategy.
“We are pleased to announce that we have entered into this term sheet, which is in line with our growth strategy to increase ownership of assets such as marketing authorisations. The transaction will strengthen Navamedic’s hospital offering with an important product range. The products are developed and manufactured by a reliable European supplier, which will underpin Navamedic’s efforts in mitigating the drug shortage situation in the Nordics,” says Kathrine Gamborg Andreassen, CEO of Navamedic.
As outlined in the term sheet, Navamedic will acquire the marketing authorisations for a series of antibiotics for hospital use in the Nordic region. The term sheet is entered into with the Italian chemical-pharmaceutical company ACS Dobfar S.p.a. and its Swiss subsidiary InfoRLife SA, a pharmaceutical company developing, registering and producing ready-to-use medicines.
The antibiotics in the portfolio are designed to be given intravenously to patients and are currently in regular use in hospitals in all the Nordic countries with an annual turnover of approximately NOK 25 million. As part of the collaboration, the parties have agreed to also enter into a long-term supply and service agreement including launch of new products in the future – potentially also outside the Nordic territory. The parties plan to complete the asset purchase agreement and supporting agreements by 31 March 2020, and to close the transaction by 30 June 2020. Further details will be given after the closing of the transaction.